(Q42661688)

English

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.

scientific article published on 23 May 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20497967%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20497967%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

David Cunningham

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20497967%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Naureen Starling

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20497967%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

S Rao

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20497967%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

K Sumpter

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20497967%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

D Gilligan

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20497967%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

T Ruhstaller

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20497967%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

M Valladares-Ayerbes

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20497967%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

H Wilke

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20497967%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

C Archer

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20497967%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

R Kurek

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20497967%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

C Beadman

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20497967%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

J Oates

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20497967%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

publication date

23 May 2010

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20497967%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20497967%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20497967%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20497967%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

2213-2219

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20497967%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Global cancer statistics in the year 2000.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Patient preferences for oral versus intravenous palliative chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Single-molecule imaging of EGFR signalling on the surface of living cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Cell signaling by receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Epidermal growth factor receptor status and S-phase fractions in gastric carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Cetuximab therapy and symptomatic hypomagnesemia

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Cetuximab-induced hypomagnesemia in patients with colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ247

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42661688&oldid=1578033386"